RoosterBio, Inc., a supplier of human mesenchymal stem/stromal cells (hMSCs), media, and bioprocess services, has announced a collaboration with Thermo Fisher Scientific to accelerate the development and manufacturing of cell and exosome therapies targeting degenerative diseases. The partnership aims to
Olon Group, a global pharmaceutical CDMO, has announced two key leadership appointments aimed at strengthening its biologics and complex molecule manufacturing services. Jérôme Bédier has been named CEO of Olon’s French entities, while Andrea Conforto will serve as M&S VP
Effective process development plays a key role in mitigating risk, accelerating time-to-market, and significantly reducing development costs for pharmaceutical companies. According to recent industry data, approximately 90% of drug candidates fail during development, with process-related challenges accounting for a significant
Kindeva, a global CDMO and drug delivery specialist, has announced the appointment of Melanie Cerullo as its new Chief Quality Officer. The move is aimed at reinforcing the company’s quality, compliance, and regulatory approach as it expands its global operations.
Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics, Inc. for $47 per share in cash. The deal values SpringWorks at approximately $3.9 billion, representing a 26% premium to its 20-day volume-weighted average price before transaction speculation began. The
ten23 health has announced the launch of its quality control (QC) and testing services at its Basel (BASE) and Visp (VIVA2) facilities, following the receipt of GMP establishment licences from Swissmedic. The services were officially inaugurated with an event attended by
At this time of increasing geopolitical tensions, Claire Greenaway – Chemical, Biological, Radiological and Nuclear (CBRN) Delivery Team at the UK Ministry of Defence – explains why she is attending CDMO Live and what opportunities are for collaboration. Claire Greenaway’s
The clinical trials sector continues experiencing substantial growth, with investigational medicinal products (IMPs) serving as the cornerstone of pharmaceutical innovation and drug development. As regulatory frameworks evolve and breakthrough therapies advance through development pipelines, understanding the intricacies of IMP development,
“In Big Pharma, innovation is often stifled because the bureaucracy and mindset completely kills creativity and intuition needed for discovery. That’s why they now prefer to allocate their early-phase resources to smaller biotechs,” explains Julien Laizé, sharing candid insights about
Quality by Design (QbD) has revolutionised pharmaceutical manufacturing, transforming how companies approach drug development and production. As regulatory agencies increasingly emphasise science-based manufacturing approaches, implementing robust QbD principles has become essential for maintaining competitive advantage whilst ensuring patient safety. This
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
